The "blind greed" saga continues.
The US National Institutes of Health said Thursday that it will fund a study to compare two drugs by Genentech used to treat the leading cause of blindness in the elderly.
One of the drugs, Lucentis, was approved by the FDA this year to treat the disorder, called age-related macular degeneration, or AMD. The other drug, Avastin, which is much cheaper, has been approved to treat colorectal cancer, although it has been widely used off-label to treat the eye condition, according to the NIH's National Eye Institute.
Both drugs are derived from the same mouse antibody.
But....
Genentech are charging around 100 times the price of Avastin for Lucentis!
Insider's view: Way to go NIH!
Posts
No comments:
Post a Comment